Comment on complications following antidotal use of intravenous lipid emulsion therapy (Levine et Al., J Med Toxicol 2013)

Affiliations

Comment

Ami M Grunbaum et al. J Med Toxicol. 2014 Jun.

. 2014 Jun;10(2):245-6.

doi: 10.1007/s13181-014-0388-1.

¹ McGill University Health Centre, Montreal, Quebec, Canada, ami.grunbaum@mail.mcgill.ca.

No abstract available

Comment on

Complications following antidotal use of intravenous lipid emulsion therapy.
Levine M, Skolnik AB, Ruha AM, Bosak A, Menke N, Pizon AF. Levine M, et al. J Med Toxicol. 2014 Mar;10(1):10-4. doi: 10.1007/s13181-013-0356-1. J Med Toxicol. 2014. PMID: 24338451 Free PMC article.

1. Levine M, Skolnik AB, Ruha AM, Bosak A, Menke N, Pizon AF (2013) Complications following antidotal use of intravenous lipid emulsion therapy. J Med Toxicol (Epub ahead of print) - PMC - PubMed
1. Grunbaum AM, Gilfix BM, Gosselin S, Blank DW. Analytical interferences resulting from intravenous lipid emulsion. Clin Toxicol (Phila) 2012;50:812–817. doi: 10.3109/15563650.2012.731509. - DOI - PubMed
1. McEnroe RJ, Burritt MF, Powers DM, Rheinheimer DW (2005) Interference testing in clinical chemistry: approved guideline—Second Edition, CLSI document EP7–A2 (ISBN 1-56238-584-4). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087–1898 USA
1. Dimeski G, Jones BW. Lipaemic samples: effective process for lipid reduction using high speed centrifugation compared with ultracentrifugation. Biochem Med. 2011;22:86–92. doi: 10.11613/BM.2011.016. - DOI - PubMed
1. Intralipid [Product monograph] (2006) Fresenius Kabi AB, Uppsala, Sweden